They report a case of endophthalmitis and undertook a literature review to identify previous infections with this pathogen.

Those who suffer from eye infections that threaten a person’s vision have a new treatment option that is noninvasive and ...

Please provide your email address to receive an email when new articles are posted on . Cold instillation was associated with significantly lower discomfort compared with warm instillation.

Further research is needed to establish the value of topical antibiotics and indications for their use with infected dermatitis and established wounds.

Eye drops are the most preferred drug delivery method in the ophthalmic market, yet developing eye drop formulations targeting the retina, located in the posterior segment of the eye, remains a ...

For moderate to severe infectious conjunctivitis or pink eye caused by bacteria, topical treatments "may reduce the duration of symptoms," says Shapiro. These may include topical antibiotics ...

Int Ophthalmol Clin. 2015;55(2):1-10. Surveys performed in 2009 indicated that >80% of retina specialists used topical antibiotics either before and/or after IVT injections. More recent surveys ...

Dec. 23, 2024 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the ...

(MENAFN- GlobeNewsWire - Nasdaq) Patent for methods of use of topical DNase enzymes in the eye covers L304, Neutrolis' proprietary therapy in development for the treatment of moderate to severe ...

Under the agreement, Neutrolis has acquired the rights to intellectual property that covers the use of topical DNase enzymes in the eye. Neutrolis is developing L304, a novel DNase generated using ...

Ointments aren’t the same as eye drops. Drops are liquid, while ointments are semisolid and greasy. These drugs generally require a prescription. However, other forms of the same antibiotics may ...

Patent for methods of use of topical DNase enzymes in the eye covers L304, Neutrolis’ proprietary therapy in development for the treatment of moderate to severe dry eye disease CAMBRIDGE, Mass., Dec.